First baby born in UK to woman with transplanted womb
A baby girl has become the first in the UK to be born from a womb transplant, after her aunt donated her uterus to her mother, a London hospital said Tuesday.
Amy was born on February 27 at the Queen Charlotte's and Chelsea Hospital in London, two years after her mum, Grace Davidson, received a womb transplant from her older sister.
"We have been given the greatest gift we could ever have asked for," the new mum said.
She added that she hoped "going forward this could become a wonderful reality, and provide an additional option, for women who would otherwise be unable to carry their own child".
"The room was full of people who have helped us on the journey to actually having Amy," her father Angus Davidson told the Press Association news agency.
"We had been kind of suppressing emotion, probably for 10 years, and you don't know how that's going to come out -—ugly crying it turns out," he added.
Grace Davidson, 36, suffers from a rare condition known as Mayer-Rokitansky-Kuster-Hauser syndrome and was born without a functioning womb, the hospital said in a statement.
She became the first woman in the UK to receive a womb transplant, which was donated by her sister Amy Purdie, 42, who has two daughters, aged 10 and six.
The transplant was performed in February 2023 at the Oxford Transplant Centre, part of the Oxford University Hospitals foundation.
Professor Richard Smith, a consultant gynaecological surgeon who co-leads the UK living donor programme, said Amy's birth was the "culmination of over 25 years of research".
More than 100 womb transplants have been carried out worldwide since the first ones in Sweden in 2013, and around 50 healthy babies have been born.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Khaleej Times
08-04-2025
- Khaleej Times
First baby born in UK to woman with transplanted womb
A baby girl has become the first in the UK to be born from a womb transplant, after her aunt donated her uterus to her mother, a London hospital said Tuesday. Amy was born on February 27 at the Queen Charlotte's and Chelsea Hospital in London, two years after her mum, Grace Davidson, received a womb transplant from her older sister. "We have been given the greatest gift we could ever have asked for," the new mum said. She added that she hoped "going forward this could become a wonderful reality, and provide an additional option, for women who would otherwise be unable to carry their own child". "The room was full of people who have helped us on the journey to actually having Amy," her father Angus Davidson told the Press Association news agency. "We had been kind of suppressing emotion, probably for 10 years, and you don't know how that's going to come out -—ugly crying it turns out," he added. Grace Davidson, 36, suffers from a rare condition known as Mayer-Rokitansky-Kuster-Hauser syndrome and was born without a functioning womb, the hospital said in a statement. She became the first woman in the UK to receive a womb transplant, which was donated by her sister Amy Purdie, 42, who has two daughters, aged 10 and six. The transplant was performed in February 2023 at the Oxford Transplant Centre, part of the Oxford University Hospitals foundation. Professor Richard Smith, a consultant gynaecological surgeon who co-leads the UK living donor programme, said Amy's birth was the "culmination of over 25 years of research". More than 100 womb transplants have been carried out worldwide since the first ones in Sweden in 2013, and around 50 healthy babies have been born.
Zawya
31-01-2025
- Zawya
Saudi Hospitals advance in brand finance's 2025 rankings
Riyadh: Saudi hospitals have made significant strides in the 2025 Brand Finance global ranking of the world's Top 250 hospitals, with seven Saudi hospitals making the list, including two in the top 100 globally. Leading the rankings regionally, King Faisal Specialist Hospital & Research Centre climbed to 15th place globally, improving from 20th place over the past two years, maintaining its position as the top healthcare institution in Saudi Arabia, the Middle East, and Africa. The Johns Hopkins Hospital in the United States secured the top position, while American hospitals dominated 10 spots of the Top 250. The list also featured several leading European hospitals, while Oxford University Hospitals surged to second place this year, becoming the highest-ranked healthcare institution outside the U.S. Based on a survey of thousands of healthcare professionals across 30+ countries, the ranking placed King Faisal Specialist Hospital & Research Centre as the leading Saudi hospital among the seven included, followed by King Fahad Medical City, King Khalid University Hospital, King Saud Medical City, King Abdullah Medical City, National Guard Health Affairs, and King Fahad University Hospital. According to analysts, the strong presence of Saudi hospitals in global rankings is attributed to initiatives under the Health Sector Transformation Program, a key pillar of Saudi Vision 2030, launched by Crown Prince Mohammed bin Salman. This achievement also reflects the unwavering support of the leadership for the healthcare sector, the high quality of services provided to citizens and residents, and the remarkable medical advancements across various specialties.
The National
27-11-2024
- The National
First new asthma attack treatment in 50 years could be 'game-changing'
The first new treatment for asthma attacks in decades could prove "game-changing" for patients, researchers say. Four people with asthma and 85 with chronic obstructive pulmonary disease (COPD), a progressive condition with symptoms similar to asthma, die every day and someone has an asthma attack every 10 seconds in the UK. About one in 10 children in the UAE are believed to have asthma. Eosinophilic exacerbations – caused by high concentrations of a type of white blood cells called eosinophils – account for about 30 per cent of flare-ups in COPD and almost half of asthma attacks. They can become more frequent as the disease progresses, leading to irreversible lung damage in some cases. Treatment for eosinophilic exacerbations has barely changed in 50 years. They are usually treated by steroids, which can reduce inflammation in the lungs, but have severe side effects such as diabetes and osteoporosis and do not always work. The new drug, benralizumab, a monoclonal antibody, targets eosinophils to reduce lung inflammation and is more effective than steroids, reducing the need for further treatment by 30 per cent. A single dose is more effective when injected at the point of exacerbation compared to a short course of steroid tablets, the study found. Lead investigator of the trial Prof Mona Bafadhel from King's College London told The National the treatment was game-changing and could be available to asthmatics within five years. "This is the first new treatment for asthma and COPD attacks in 50 years," she said. "The treatment really did improve people's symptoms within 28 days and also reduced the number of times they had treatment failures by a factor of four-fold. So it was quite a big reduction. We estimate in the UK it would be suitable for two million attacks every year, just in one country." Researchers randomised people at high risk of an asthma or COPD attack into three groups: one receiving benralizumab injection and dummy tablets; one receiving prednisolone steroids for five days and dummy injection; and the third group receiving both benralizumab injection and prednisolone steroids for five days. Neither investigators nor the people involved in the study, which was conducted at Oxford University Hospitals NHS Foundation Trust, and Guy's and St Thomas' NHS Foundation Trust, knew what treatment they received. After 28 days, respiratory symptoms of cough, wheeze, breathlessness and sputum were found to be better with benralizumab. And after 90 days, there were four times fewer people in the benralizumab group that "failed treatment" compared to standard care with prednisolone. Patients had to have high eosinophils for the injection to be given, said Prof Bafadhel. To determine that, researchers tested their blood at the time of the attack. "You can get a full blood count reading within 20 minutes and in other places you can actually do a pinprick blood test. The future is not that far away from being able to do that," she said. Patients who received the benralizumab injection had fewer episodes that required a doctor appointment or hospital visit. There was also an improvement in quality of life for people with asthma and COPD. The under-the-skin injection, which does not need to go directly into a vein, was administered by healthcare professionals in the study but can be potentially given safely at home, in a GP practice or in an emergency department. Dr Sanjay Ramakrishnan, clinical senior lecturer at the University of Western Australia, who is the first author of the trial and started the work while at the University of Oxford, said the drug shows "massive promise" for asthma and COPD treatment. "COPD is the third leading cause of death worldwide but treatment for the condition is stuck in the 20th century. We need to provide these patients with life-saving options before their time runs out," he said. Dr Samantha Walker, director of research and innovation at Asthma + Lung UK, said the findings were promising for patients. "But it's appalling that this is the first new treatment for those suffering from asthma and COPD attacks in 50 years, indicating how desperately underfunded lung health research is," she said. The paper was published in The Lancet Respiratory Medicine.
